News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Latest News
AB Science Secures Loan Repayment Deferrals to Fund R&D Operations Through 2028
AB Science reaches agreement with creditors for 2-year state loan deferral and 12-month EIB credit extension, redirecting savings to R&D investments.
Mundipharma's REZZAYO (Rezafungin) Meets Primary Endpoint in Phase III ReSPECT Trial for Fungal Disease Prevention
Mundipharma announces positive Phase III ReSPECT trial results for REZZAYO (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients.
Crinetics Pharmaceuticals Receives EU Approval for PALSONIFY (Paltusotine), First Oral Daily Acromegaly Treatment
Crinetics Pharmaceuticals announces European Commission approval of PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly in adults.
Reuters Pharma: AI & Patient-Centricity Take Center Stage
Reuters Pharma 2026 highlighted AI integration and patient-centric commercial models as transformative forces reshaping drug development and market access strategies. Access innovation and data readiness emerged as critical competitive differentiators.
Pharma 2026: Key Takeaways from EU Biopharma & Medtech
Q1 2026 biopharma and medtech markets showed selective momentum with $5.2B venture funding, $77.3B licensing deals, and investor focus on proof over promise—rewarding clinical differentiation and commercial execution over speculative science.
Reuters Pharma EU: Funding & Dealmaking Key Takeaways
Q1 2026 biopharma funding reached $5.2B in venture capital, with licensing deals totaling $77.3B and M&A activity hitting $15.6B—exceeding full-year 2025 totals. Selective investor optimism rewards proven clinical progress in oncology, neurology, rare diseases, and obesity therapeutics.
ASCO 2026: Olverembatinib Data & Gastric Cancer Trial Updates
Ascentage Pharma and Ono Pharma will present key oncology trial data at ASCO 2026, covering advancements in leukemia and gastric cancer treatments.
Pharma Sustainability 2026: Packaging Innovation Preview
Pharma Sustainability 2026 emphasizes sustainable packaging solutions, the transition to circular economy models, and recyclable mono-materials like PharmaGuard®.
Boston Scientific Corporation Faces Securities Class Action Lawsuit with May 4 Deadline for Investors
Boston Scientific investors have until May 4, 2026 to join securities class action lawsuit. Rosen Law Firm encourages shareholders to secure legal counsel.
Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis
Brii Bio's elebsiran combined with pegylated interferon demonstrates sustained HBsAg loss and favorable off-treatment outcomes in hepatitis B patients.
EMA Issues Positive Opinion for Rexatilux (Ranibizumab) Eye Treatment
European Medicines Agency issues positive opinion for Rexatilux ranibizumab, advancing potential new eye treatment option for European patients.
EMA Issues Positive Opinion for Redemplo (Plozasiran) in European Drug Approval Process
European Medicines Agency issues positive opinion for Redemplo (plozasiran) marking significant step toward EU market authorization for this novel therapy.
EMA Issues Positive Opinion for Viatris' Palbociclib Generic Cancer Treatment
European Medicines Agency issues positive opinion for Viatris' generic palbociclib, potentially expanding access to this important breast cancer treatment.
EMA Issues Positive Opinion for Itvisma (Onasemnogene Abeparvovec) Gene Therapy for Spinal Muscular Atrophy
European Medicines Agency issues positive opinion for Itvisma, a one-time gene therapy for spinal muscular atrophy in infants and children.
EMA Issues Positive Opinion for Cenrifki (Tolebrutinib) Multiple Sclerosis Treatment
European Medicines Agency issues positive opinion for Cenrifki (tolebrutinib), a potential new oral treatment for multiple sclerosis patients.
EMA Recommends First RNA-Based Veterinary Vaccine Nobivac NXT HCPChFeLV for Cats
European Medicines Agency recommends Nobivac NXT HCPChFeLV, the first RNA-based veterinary vaccine for cats, marking breakthrough in animal health technology.
EMA Recommends Approval of Plozasiran (Redemplo) for Rare Triglyceride Disorder FCS
European Medicines Agency recommends plozasiran (Redemplo) for marketing authorization to treat adults with familial chylomicronaemia syndrome in EU.
EMA CHMP Recommends Five New Medicines Including Tolebrutinib (Cenrifki) for Approval in April 2026
European Medicines Agency's CHMP committee recommended five new medicines for approval in April 2026, including tolebrutinib (Cenrifki) for multiple sclerosis treatment.
Aetna Standardizes 88% of Prior Authorization Volume, Exceeds Industry Commitments for Healthcare Access
Aetna announces 88% prior authorization standardization, surpassing industry goals while maintaining fewest medical service requirements among national health plans.
Guerbet's Lipiodol Ultra Fluid Achieves EU Regulatory Milestone for Vascular Embolization Procedures
Guerbet announces positive EU regulatory outcome for Lipiodol Ultra Fluid in vascular embolization, expanding interventional radiology applications.